内地-外地を結ぶ書物のネットワークと朝鮮半島の小売書店 :日配時代を中心に

HIBI Yoshitaka 한림대학교 일본학연구소 2015 翰林日本學 Vol.0 No.27

This paper presents an investigation into the book distribution network to connect the in and outside of Japan before the World War II with a special focus on the distribution network to connect Japan with the Korean Peninsula after the foundation of Japanese Publishing and Distribution Corporation. The study also mentioned the forms of retail bookstores around the Korean Peninsula during those days. The activities of Japanese Publishing and Distribution Corporation are recorded in History of Japanese Publishing and Distribution Corporation, which depicts its detailed history sorted out by the persons concerned later. As its title indicates, it records the overall affairs and organizational changes of the Corporation in a chronological order and makes it difficult to grasp the outlines of certain themes and areas due to the scattered information about them throughout the material. Consulting its records, the present study crossed it with publications issued by it including Communication of Japanese Publishing and Distribution Corporation, Publishing and Distribution, Promotion of New Books, Promotion of Publication, and others, looked into the actual state of book distribution around the Korean Peninsula, and examined the actual state of retail bookstores in Joseon. Those investigative efforts helped to understand an aspect of distribution process for books written in Japanese around the Korean Peninsula at the end of Japanese Empire. The findings about the progress of book sales were also expected to reveal the contacts, symbiosis, and clash patterns between Japanese and Korean people. During the war, the Japanese imperialists tried to control every aspect of society. The publishers belonging to an organization had to transform their businesses to follow the national power. The organizations of publishers had themselves in line with the national 50 한림일본학 27집policies and deteriorated into the tools of power, which was forced and, at the same time, voluntary as members of organization. It is a piece of history and the past that is accompanied by criticism and reflection, offering a lesson for modern Koreans. It cannot help being limited, however, to look into only the power and control aspects. The movements of culture moving inside a social device are diverse, and a social system itself can exist and function separate from ideology. The central book distribution system realized by the Japanese Publishing and Distribution Corporation, for instance, developed into a relay system in Japan after the war. 本論文では、第二次世界大戦以前における日本内地と外地を結んだ書物流通ネットワークの考察を行った。とりわけ、重点的に検討したのが日本出版配給株式会社(日配)成立以降における内地と朝鮮半島とを結んだ流通網である。また関連して、この時期の朝鮮半島における小売書店のあり方についても言及した。日配の活動については、関係者が後年まとめた詳細な歴史『日配時代史』が存在する。ただしこの資料は名前の示す通り、日配全体の業務や組織の変遷を、おおむね編年体で追いかけるものであり、特定のテーマや地域については情報が分散していて輪郭が掴みにくい。今回は、『日配時代史』の記述を参考にしながら、そこに日配が刊行していた冊子『日配通信』『出版普及』『新刊弘報』『出版弘報』他を交差させ、朝鮮半島を舞台とした書物流通の実態に迫り、また日配関連資料である『日配通信』や『出版普及』『新刊弘報』なども取り扱った。また、朝鮮半島の小売書店の実態についても、報告を行い、これらの作業により、日本帝国主義時代末期の朝鮮半島における日本語書物の流通過程の一端が明らかになるとともに、書物の売買を通した日本人、朝鮮人の接触と共棲、衝突のありさまが浮かび上がっていくものと考えている。 戦時国家は、社会を隅から隅まで統制しようとした。出版人たちは、組織に所属していればいるほど、国家権力に沿うかたちに自からと、自からの所属する組織を変えていかなければならなかった。かくして、出版業の諸団体は国策と一体化し、権力の手先と化した。彼らはそれを強制されて行ったが、しかし同時に組織人としてそれを自主的にも行った。それは批判されるべき歴史であり、反省を引き継ぐべき過去である。そして、現代においてなお顧みるべき教訓でもある。だが、そうした権力と統制の側だけみるのは、時代の一部分でしかあるまい。社会装置の上で駆動する文化の動態は、より多様であり、社会装置そのものはイデオロギーとは別に存続し機能しうる。たとえば、日配が実現した書物の一元配給システムは、戦後日本の高度な取次システムへと引き継がれた。

Pathogenesis: Any Differences from that of Western Countries ?

( Toshifumi Hibi ) 대한소화기학회 2005 SIDDS Vol.8 No.-

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis

( Toshifumi Hibi ),( Isao Kamae ),( Philippe Pinton ),( Lyann Ursos ),( Ryuichi Iwakiri ),( Greg Hather ),( Haridarshan Patel ) 대한장연구학회 2021 Intestinal Research Vol.19 No.1

Background/Aims: Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We compared the efficacy of biologics approved in Japan (adalimumab, infliximab, golimumab, and vedolizumab) for treating biologic-naïve patients with UC at their approved doses. Methods: A targeted literature review identified 4 randomized controlled trials of biologics for UC in biologic-naïve Japanese patients. For each study, efficacy outcome data from induction (weeks 6-12) and maintenance (weeks 30-60) treatment were extracted for analysis. Treatment effects on clinical response, clinical remission, and mucosal healing relative to the average placebo results across all trials were estimated using network meta-analyses followed by transformation into probabilities and odds ratios (OR). Results: At the end of induction, the likelihood of clinical response and clinical remission was highest with infliximab (OR: 2.12 and 2.35, respectively) and vedolizumab (OR: 2.10 and 2.32, respectively); the likelihood of mucosal healing was highest with infliximab (OR: 2.24) and adalimumab (OR: 1.86). During maintenance, the likelihood of clinical response and clinical remission was highest with vedolizumab (OR: 6.44 and 4.68, respectively) and golimumab (OR: 5.13 and 3.84, respectively); the likelihood of mucosal healing was significantly higher than placebo with all biologics. Conclusions: All active treatments were efficacious compared with placebo. Infliximab and vedolizumab had the highest odds for induction of clinical response, remission, and mucosal healing. Golimumab and vedolizumab had numerically higher odds of achieving efficacy outcomes in the maintenance phase. (Intest Res 2021;19:53-61)

How can we educate the best surgeon or surgical oncologist in the POST COVID era?

Taizo Hibi 대한종양외과학회 2022 대한임상종양학회 학술대회지 Vol.2022 No.2

Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study

Toshifumi Hibi,Satoshi Motoya,Toshifumi Ashida,Souken Sai,Yukinori Sameshima,Shiro Nakamura,Atsuo Maemoto,Masahiro Nii,Barbara A Sullivan,Robert A. Gasser Jr,Yasuo Suzuki 대한장연구학회 2019 Intestinal Research Vol.17 No.3

Background/Aims: Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of the α4β7 inhibitor abrilumab in Japanese patients with moderate-to-severe UC despite conventional treatments. Methods: In this randomized, double-blind, placebo-controlled study, 45 UC patients were randomized to abrilumab 21 mg (n=11), 70 mg (n=12), 210 mg (n=9), or placebo (n=13) via subcutaneous (SC) injection for 12 weeks. The double-blind period was followed by a 36-week open-label period, in which all patients received abrilumab 210 mg SC every 12 weeks, and a 28-week safety follow-up period. The primary efficacy variable was clinical remission at week 8 (total Mayo score ≤2 points with no individual subscore >1 point). Results: Clinical remission at week 8 was 4 out of 31 (12.9%) overall in the abrilumab groups versus 0 out of 13 in the placebo group (abrilumab 21 mg, 1/10 [10.0%]; 70 mg, 2/12 [16.7%]; 210 mg, 1/9 [11.1%]). In both the double-blind and open-label periods, fewer patients in the abrilumab groups experienced ≥1 adverse event compared with those in the placebo group. There were no cases of progressive multifocal leukoencephalopathy and no deaths. Conclusions: Abrilumab 70 mg and 210 mg yielded numerically better results in terms of clinical remission rate at Week 8 than placebo, with the 210 mg dose showing more consistent treatment effects. Abrilumab was well tolerated in Japanese patients with UC.

Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials

( Toshifumi Hibi ),( Makoto Naganuma ),( Eisei Oda ),( Yoji Yamada ),( Yoshitomo Chujoh ),( Ryoichi Yoshihara ),( Mamoru Watanabe ) 대한장연구학회 2020 Intestinal Research Vol.18 No.1

Background/Aims: Mucosal healing (MH) of distal lesions in ulcerative colitis (UC) has recently been confirmed with budesonide 2-mg foam (BF) treatment in 2 clinical trials; however, few studies have investigated the predictive factors for complete MH. Methods: We conducted a post hoc analysis using pooled data from phase II and III clinical trials evaluating the efficacy and safety of BF for UC. Additionally, we analyzed the relationships between complete MH and baseline factors and clinical symptoms from baseline to week 6. Results: Among the 291 Japanese patients from the 2 pooled clinical studies, 119 patients in the BF twice a day group and 117 in the placebo group were included in the full analysis set. The proportion of patients with a rectal bleeding (RB) subscore of 0 was significantly higher in the BF group than in the placebo group after a 5-day treatment (P<0.05). After a 2-day treatment, significantly more patients in the BF group had a stool frequency (SF) subscore of 0 than patients in the placebo group (P<0.05). Multivariate analysis showed that complete MH at week 6 was influenced by baseline SF subscore and 5-aminosalicylic acid (5-ASA) enema or suppository use (P=0.0086 and P=0.0015, respectively). The relationship between complete MH at week 6 and RB subscore after week 2 was also confirmed. Conclusions: Normal SF at baseline, history of 5-ASA topical product use, and elimination of RB after week 2 are suggested predictors of complete MH at week 6 with twice-daily BF treatment. (Intest Res 2020;18:56-68)

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn’s disease: a subpopulation analysis of phase 3 induction and maintenance studies

( Toshifumi Hibi ),( Yuya Imai ),( Yoko Murata ),( Nobuko Matsushima ),( Richuan Zheng ),( Christopher Gasink ) 대한장연구학회 2017 Intestinal Research Vol.15 No.4

Background/Aims: Efficacy and safety of ustekinumab were evaluated in a Japanese subpopulation with moderately to severely active Crohn’s disease (CD) in UNITI-1, UNITI-2 and IM-UNITI studies and results were compared with the overall population. Methods: Overall, patients in UNITI-1 (Japan, n=56; failed response to tumor necrosis factor antagonist) and UNITI-2 (Japan, n=26; failed response to prior conventional therapy) were randomized to placebo or ustekinumab intravenous induction (130 mg or ~6 mg/kg) at week 0. Responders to ustekinumab induction therapy (Japan, n=21) were randomized to placebo or ustekinumab (90 mg, subcutaneous) maintenance (every 12 weeks [q12w] or 8 weeks [q8w]) in IM-UNITI. The primary endpoint was clinical response at week 6 for induction studies and clinical remission at week 44 for maintenance study. Results: Percentage of patients achieving clinical response at week 6 was greater in ustekinumab 130 mg and ~6 mg/kg groups than in the placebo group (UNITI-1: 36.8% and 31.6% vs. 27.8%, respectively, for Japanese; 34.3% and 33.7% vs. 21.5%, respectively, for overall; UNITI-2: 37.5% and 55.6% vs. 11.1%, respectively, for Japanese; 51.7% and 55.5% vs. 28.7%, respectively, for overall). Clinical remission rate at week 44 during maintenance was greater in the ustekinumab 90 mg SC q12w and q8w groups than in the placebo group (50.0% and 55.6% vs. 25.0%, respectively, for Japanese; 48.8% and 53.1% vs. 35.9%, respectively, for overall). Efficacy and safety results observed in the Japanese subpopulation were generally consistent with those in the overall population. Conclusions: Ustekinumab could be considered as a new therapeutic option for moderately to severely active CD in Japanese patients. Both ustekinumab induction and maintenance treatments were generally well tolerated (Clinical Trial Registration: NCT01369329, NCT01369342, NCT01369355). (Intest Res 2017;15:475-486)

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

Toshifumi Hibi,Satoshi Motoya,Tadakazu Hisamatsu,Fumihito Hirai,Kenji Watanabe,Katsuyoshi Matsuoka,Masayuki Saruta,Taku Kobayashi,Brian G Feagan,Chantal Tasset,Robin Besuyen,Chohee Yun,Gerald Crans,Ji 대한장연구학회 2023 Intestinal Research Vol.21 No.1

Background/Aims: The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial. Methods: SELECTION (NCT02914522) was a randomized, placebo-controlled trial comprising 2 induction studies and a maintenance study. Adults with moderately to severely active UC were randomized in induction study A (biologic-naïve) or B (biologic-experienced) to receive filgotinib 200 mg, 100 mg, or placebo once daily for 11 weeks. Patients in clinical remission or Mayo Clinic score response at week 10 entered the 47-week maintenance study. Efficacy and safety outcomes were assessed in Japanese patients enrolled in Japan. Results: Overall, 37 and 72 Japanese patients were enrolled in Japan in induction studies A and B, respectively, and 54 entered the maintenance study. Numerically higher proportions of filgotinib 200 mg-treated than placebo-treated patients achieved clinical remission in induction study A (4/15 [26.7%] vs. 0/6 [0%]) and the maintenance study (5/20 [25.0%] vs. 0/9 [0%]), but not induction study B (1/29 [3.4%] vs. 1/14 [7.1%]). Both doses were well tolerated, and no new safety signals were noted. Herpes zoster was reported in 1 filgotinib 200 mg-treated patient in each of induction study A (2.3%, 1/44) and the maintenance study (5.0%, 1/20). Conclusions: These data, alongside those of the overall SELECTION population, suggest the potential of filgotinib 200 mg as a viable treatment option for Japanese patients with UC. Owing to small patient numbers, data should be interpreted cautiously.

Old Problems and New Challenges Biological Therapy For IBD How Much Progress Are We Making?

( Toshifumi Hibi ) 대한소화기학회 2007 SIDDS Vol.9 No.-

A new start for "Intestinal Research" as an official journal of AOCC

( Toshifumi Hibi ) 대한장연구학회 2016 Intestinal Research Vol.14 No.1